Partnership includes advances in macrophage-targeted antibody therapies for cancer
Makomics, a company specializing in macrophage drug discovery, has announced the launch of a global drug discovery collaboration with Ono Pharmaceutical.
The duo will develop new immuno-oncology antibody drugs against novel macrophage targets of interest in the oncology area.
As part of the agreement, Macomics will identify antibody candidates against new targets of interest by incorporating the company’s ENIGMACTM macrophage drug discovery platform. Ono, meanwhile, has an exclusive option to license global rights to the candidate for further commercialization and development.
Macomics’ ENIGMAC macrophage drug discovery platform integrates large amounts of human data, custom cell models and proprietary human macrophage genome editing capabilities to discover novel targets and unlock disease-specific target biology.
Under these terms, Macomics will also receive upfront payments, research and development funds, milestone payments based on success, and tiered royalties based on global sales.
Toichi Takino, executive director of drug discovery and research at Ono Pharmaceutical, was optimistic about the potential for life-changing collaborations. change the lives of cancer patients. ”
“Macomics has demonstrated the power of their macrophage platform and drug discovery approach, and we are pleased to partner with them to advance this novel target discovery program.”
Macomics CEO Stephen Myatt concludes: Ono is a leader in immuno-oncology and we are pleased to have a partner at Ono who brings the complementary skills needed to succeed in this therapeutic area. ”
